FDA Approval to Market a New Drug

Forms and Documents

Document Name	Status
pra0001 ss 2008.doc Supporting Statement A	2008-04-14

IC Document Collections

IC ID	Document Title	Status
5662	FDA Approval to Market a New Drug Other-Other	Modified
184611	FDA Approval to Market a New Drug Other-Other	New
184610	FDA Approval to Market a New Drug Other-Other	New
184609	FDA Approval to Market a New Drug Other-Other	New
184608	FDA Approval to Market a New Drug Other-Other	New
184607	FDA Approval to Market a New Drug Other-Other	New
184606	FDA Approval to Market a New Drug Other-Other	New
184605	FDA Approval to Market a New Drug Other-Other	New
184604	FDA Approval to Market a New Drug Other-Other	New
184603	FDA Approval to Market a New Drug Other-Other	New
184602	FDA Approval to Market a New Drug Other-Other	New
184601	FDA Approval to Market a New Drug Other-Other	New
184600	FDA Approval to Market a New Drug Other-Other	New
184599	FDA Approval to Market a New Drug Other-Other	New
184598	FDA Approval to Market a New Drug Other-Other	New
184597	FDA Approval to Market a New Drug Other-Other	New
184596	FDA Approval to Market a New Drug Other-Other	New
184595	FDA Approval to Market a New Drug Other-Other	New
184594	FDA Approval to Market a New Drug Other-Other	New
184593	FDA Approval to Market a New Drug Other-Other	New
184592	FDA Approval to Market a New Drug Other-Other	New
184591	FDA Approval to Market a New Drug Other-Other	New

ICR Details

OMB Control No: 0910-0001	ICR Reference No: 200804-0910-004
Status: Historical Active	Previous ICR Reference No: 200608-0910-003
Agency/Subagency: HHS/FDA	Agency Tracking No:
Title: FDA Approval to Market a New Drug
Type of Information Collection: Extension without change of a currently approved collection	Common Form ICR:  No
Type of Review Request: Regular
OIRA Conclusion Action: Approved without change	Conclusion Date: 05/29/2008
	Date Received in OIRA: 04/23/2008
Terms of Clearance:

	Inventory as of this Action	Requested	Previously Approved
Expiration Date	05/31/2011	36 Months From Approved	05/31/2008
Responses	56,664	0	336,956
Time Burden (Hours)	2,836,796	0	2,581,083
Cost Burden (Dollars)	0	0	0

---

Abstract: Section 505 of the Food, Drug, and Cosmetic Act requires that a new drug may not be marketed unless the manufacture provides FDA with scientific evidence that the drug is both safe and effective. The regulations at 21 CFR Part 314 provide the means through which pharmaceutical manufacturers can obtain FDA approval of a drug product marketing application, and the means through which FDA can assure the safety and effectiveness of the marketed products.

---

Authorizing Statute(s): None

Citations for New Statutory Requirements: None

---

Associated Rulemaking Information
RIN:	Stage of Rulemaking:	Federal Register Citation:	Date:
	Not associated with rulemaking

---

Federal Register Notices & Comments
60-day Notice:	Federal Register Citation:	Citation Date:
	73 FR 865	01/04/2008
30-day Notice:	Federal Register Citation:	Citation Date:
	73 FR 21139	04/18/2008
Did the Agency receive public comments on this ICR? No

---

Number of Information Collection (IC) in this ICR: 22

IC Title	Form No.	Form Name
FDA Approval to Market a New Drug
FDA Approval to Market a New Drug
FDA Approval to Market a New Drug
FDA Approval to Market a New Drug
FDA Approval to Market a New Drug
FDA Approval to Market a New Drug
FDA Approval to Market a New Drug
FDA Approval to Market a New Drug
FDA Approval to Market a New Drug
FDA Approval to Market a New Drug
FDA Approval to Market a New Drug
FDA Approval to Market a New Drug
FDA Approval to Market a New Drug
FDA Approval to Market a New Drug
FDA Approval to Market a New Drug
FDA Approval to Market a New Drug
FDA Approval to Market a New Drug
FDA Approval to Market a New Drug
FDA Approval to Market a New Drug
FDA Approval to Market a New Drug
FDA Approval to Market a New Drug
FDA Approval to Market a New Drug

---

ICR Summary of Burden

	Total Approved	Previously Approved	Change Due to New Statute	Change Due to Agency Discretion	Change Due to Adjustment in Estimate	Change Due to Potential Violation of the PRA
Annual Number of Responses	56,664	336,956	0	0	-280,292	0
Annual Time Burden (Hours)	2,836,796	2,581,083	0	0	255,713	0
Annual Cost Burden (Dollars)	0	0	0	0	0	0

Burden increases because of Program Change due to Agency Discretion: No

Burden Increase Due to:

Burden decreases because of Program Change due to Agency Discretion: No

Burden Reduction Due to:

Short Statement:

---

Annual Cost to Federal Government: $192,050,000

Does this IC contain surveys, censuses, or employ statistical methods? No

Is the Supporting Statement intended to be a Privacy Impact Assessment required by the E-Government Act of 2002? No

Is this ICR related to the Affordable Care Act [Pub. L. 111-148 & 111-152]? Uncollected

Is this ICR related to the Dodd-Frank Wall Street Reform and Consumer Protection Act, [Pub. L. 111-203]? Uncollected

Is this ICR related to the American Recovery and Reinvestment Act of 2009 (ARRA)? Uncollected

Is this ICR related to the Pandemic Response? Uncollected

---

Common Form ICR:  No

---

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).

The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:

(a) It is necessary for the proper performance of agency functions;

(b) It avoids unnecessary duplication;

(c) It reduces burden on small entities;

(d) It uses plain, coherent, and unambiguous language that is understandable to respondents;

(e) Its implementation will be consistent and compatible with current reporting and recordkeeping practices;

(f) It indicates the retention periods for recordkeeping requirements;

(g) It informs respondents of the information called for under 5 CFR 1320.8 (b)(3) about:

(i) Why the information is being collected;

(ii) Use of information;

(iii) Burden estimate;

(iv) Nature of response (voluntary, required for a benefit, or mandatory);

(v) Nature and extent of confidentiality; and

(vi) Need to display currently valid OMB control number;

(h) It was developed by an office that has planned and allocated resources for the efficient and effective management and use of the information to be collected.

(i) It uses effective and efficient statistical survey methodology (if applicable); and

(j) It makes appropriate use of information technology.

If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.

Certification Date: 04/23/2008

---